key: cord-0976881-mvxdagfi
authors: Patel, Shreya; Thompson, Misty D.; Slaven, James E.; Sanders, Don B.; Ren, Clement L.
title: Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID‐19 pandemic
date: 2021-01-12
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.25250
sha: be1eb016d800d6950c82ef5a4084819d6fc4c4a1
doc_id: 976881
cord_uid: mvxdagfi

To assess the impact of COVID‐19 restrictions on cystic fibrosis (CF) pulmonary exacerbations (PEx) we performed a retrospective review of PEx events at our CF Center and compared the rate of PEx in 2019 versus 2020. Restrictions on social interaction due to the COVID‐19 pandemic were associated with a lower number of PEx events at our pediatric CF Center, suggesting that these restrictions also reduced exposure to other respiratory viral infection in children with CF.

COVID-19, cystic fibrosis, epidemiology, exacerbation To The Editor,

The COVID-19 pandemic resulted in widespread restrictions on social interactions and lockdowns in many areas of the world. 1 The impact of these measures on cystic fibrosis (CF) pulmonary exacerbations (PEx) has not been described. Respiratory viral infections are a common trigger for PEx, 2,3 and COVID-19 restrictions might lead to fewer PEx by reducing exposure to viruses in general, not just SARS-CoV2. To test the hypothesis that the COVID-19 lockdown would be associated with a lower PEx incidence we compared PEx data at our CF Center from the time with the most stringent restrictions in Indiana to the same time interval in 2019.

We identified PEx events by performing a retrospective chart review of children with CF followed at the CF Center at Riley Hospital for Children. We limited the lower age range to 2 years because differentiating viral upper respiratory infection from PEx can be difficult in this age group, 4 and we set an upper age limit of 11 years to avoid any potential confounding by elexacaftor/tezacaftor/ivacaftor therapy. 5, 6 The first COVID-19 case in Indiana was reported on March 1, and the peak incidence of infection during the Spring 

The data are not publicly available due to privacy or ethical restrictions. 

Disease control, civil liberties, and mass testing -calibrating restrictions during the covid-19 pandemic

Clinical impact of respiratory virus in pulmonary exacerbations of children with cystic fibrosis

The role of respiratory viruses in cystic fibrosis

Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Decreased influenza activity during the COVID-19 pandemic-United States

COVID-19 public health measures and respiratory syncytial virus

Reduction of Pulmonary Exacerbations in Young Children with Cystic Fibrosis During the COVID-19